Skip to main content
. 2017 Oct 4;18:456. doi: 10.1186/s13063-017-2201-3

Fig. 1.

Fig. 1

Schematic of the four projects involved in the ExPeCT trial. BMI body mass index, CTC circulating tumour cell, H&E haematoxylin and eosin, NK natural killer, TNF tumour necrosis factor